• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一类用于二项和生存数据的两样本非参数统计方法。

A class of two-sample nonparametric statistics for binary and time-to-event outcomes.

机构信息

Department of Statistics and Operations Research, 16767Universitat Politècnica de Catalunya, Barcelona, Spain.

Center for Medical Statistics, Informatics and Intelligent Systems, 27271Medical University of Vienna, Vienna, Austria.

出版信息

Stat Methods Med Res. 2022 Feb;31(2):225-239. doi: 10.1177/09622802211048030. Epub 2021 Dec 6.

DOI:10.1177/09622802211048030
PMID:34870495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8829729/
Abstract

We propose a class of two-sample statistics for testing the equality of proportions and the equality of survival functions. We build our proposal on a weighted combination of a score test for the difference in proportions and a weighted Kaplan-Meier statistic-based test for the difference of survival functions. The proposed statistics are fully non-parametric and do not rely on the proportional hazards assumption for the survival outcome. We present the asymptotic distribution of these statistics, propose a variance estimator, and show their asymptotic properties under fixed and local alternatives. We discuss different choices of weights including those that control the relative relevance of each outcome and emphasize the type of difference to be detected in the survival outcome. We evaluate the performance of these statistics with small sample sizes through a simulation study and illustrate their use with a randomized phase III cancer vaccine trial. We have implemented the proposed statistics in the R package SurvBin, available on GitHub (https://github.com/MartaBofillRoig/SurvBin).

摘要

我们提出了一类用于检验比例相等和生存函数相等的两样本统计量。我们的建议基于比例差异的得分检验和基于加权 Kaplan-Meier 统计量的生存函数差异检验的加权组合。所提出的统计量是完全非参数的,不依赖于生存结果的比例风险假设。我们给出了这些统计量的渐近分布,提出了一个方差估计量,并在固定和局部替代假设下展示了它们的渐近性质。我们讨论了不同的权重选择,包括那些控制每个结果的相对相关性的权重,并强调了在生存结果中要检测的差异类型。我们通过模拟研究评估了这些统计量在小样本量下的性能,并通过随机化 III 期癌症疫苗试验说明了它们的用法。我们已经在 R 包 SurvBin 中实现了所提出的统计量,该包可在 GitHub 上获得(https://github.com/MartaBofillRoig/SurvBin)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6e8/8829729/4a95baa33448/10.1177_09622802211048030-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6e8/8829729/8fd396941700/10.1177_09622802211048030-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6e8/8829729/0ec976f2d43e/10.1177_09622802211048030-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6e8/8829729/4a95baa33448/10.1177_09622802211048030-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6e8/8829729/8fd396941700/10.1177_09622802211048030-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6e8/8829729/0ec976f2d43e/10.1177_09622802211048030-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6e8/8829729/4a95baa33448/10.1177_09622802211048030-fig3.jpg

相似文献

1
A class of two-sample nonparametric statistics for binary and time-to-event outcomes.一类用于二项和生存数据的两样本非参数统计方法。
Stat Methods Med Res. 2022 Feb;31(2):225-239. doi: 10.1177/09622802211048030. Epub 2021 Dec 6.
2
A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.一种基于Kaplan-Meier曲线加权差异的用于检验两个生存函数是否相等的通用方法。
Stat Med. 2015 Dec 10;34(28):3680-95. doi: 10.1002/sim.6591. Epub 2015 Jul 20.
3
Comparison of survival distributions in clinical trials: A practical guidance.临床试验中生存分布的比较:实用指南。
Clin Trials. 2020 Oct;17(5):507-521. doi: 10.1177/1740774520928614. Epub 2020 Jun 27.
4
Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.加权对数秩检验和基于 Kaplan-Meier 的检验的样本量和功效,允许非比例风险。
Biometrics. 2020 Sep;76(3):939-950. doi: 10.1111/biom.13196. Epub 2019 Dec 23.
5
Comparison of methods for estimating the attributable risk in the context of survival analysis.生存分析背景下可归因风险估计方法的比较
BMC Med Res Methodol. 2017 Jan 23;17(1):10. doi: 10.1186/s12874-016-0285-1.
6
Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.在不假设风险比例的情况下,提高对具有生存结局的随机试验分析的精度。
Lifetime Data Anal. 2019 Jul;25(3):439-468. doi: 10.1007/s10985-018-9428-5. Epub 2018 Feb 28.
7
Approximate nonparametric corrected-score method for joint modeling of survival and longitudinal data measured with error.用于对含测量误差的生存数据和纵向数据进行联合建模的近似非参数校正得分法。
Biom J. 2011 Jul;53(4):557-77. doi: 10.1002/bimj.201000180.
8
Comparison of methods to testing for differential treatment effect under non-proportional hazards data.非比例风险数据下测试差异化处理效应方法的比较。
Math Biosci Eng. 2023 Sep 15;20(10):17646-17660. doi: 10.3934/mbe.2023784.
9
Subgroup detection and sample size calculation with proportional hazards regression for survival data.使用比例风险回归对生存数据进行亚组检测和样本量计算。
Stat Med. 2017 Dec 20;36(29):4646-4659. doi: 10.1002/sim.7441. Epub 2017 Aug 8.
10
Introducing a new estimator and test for the weighted all-cause hazard ratio.引入一种新的加权全因风险比估计量和检验方法。
BMC Med Res Methodol. 2019 Jun 11;19(1):118. doi: 10.1186/s12874-019-0765-1.

本文引用的文献

1
Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.基于 Fleming-Harrington 类权重的加权对数秩统计量最大值的组序贯监测在肿瘤学临床试验中的应用。
Stat Methods Med Res. 2020 Dec;29(12):3525-3532. doi: 10.1177/0962280220931560. Epub 2020 Jun 10.
2
Joint modeling of binary response and survival for clustered data in clinical trials.临床试验中聚类数据二项反应和生存的联合建模。
Stat Med. 2020 Feb 10;39(3):326-339. doi: 10.1002/sim.8403. Epub 2019 Nov 28.
3
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
iHIVARNA Ⅱa 期,一项随机、安慰剂对照、双盲试验,旨在评估 iHIVARNA-01 在稳定联合抗逆转录病毒治疗的慢性 HIV 感染患者中的安全性和免疫原性。
Trials. 2019 Jun 17;20(1):361. doi: 10.1186/s13063-019-3409-1.
4
Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.晚期癌症免疫疗法研究设计中的统计挑战。
Cancer Immunol Res. 2015 Dec;3(12):1292-8. doi: 10.1158/2326-6066.CIR-15-0260.
5
Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes.将魏-拉钦多变量单向检验应用于多个事件时间结局。
Clin Trials. 2015 Dec;12(6):627-33. doi: 10.1177/1740774515601027. Epub 2015 Sep 2.
6
Mixed response and time-to-event endpoints for multistage single-arm phase II design.多阶段单臂II期设计的混合反应和事件发生时间终点
Trials. 2015 Jun 4;16:250. doi: 10.1186/s13063-015-0743-9.
7
Outcomes and endpoints in cancer trials: bridging the divide.癌症试验中的结局和终点:弥合分歧。
Lancet Oncol. 2015 Jan;16(1):e43-52. doi: 10.1016/S1470-2045(14)70380-8. Epub 2014 Dec 29.
8
Traditional multiplicity adjustment methods in clinical trials.临床试验中的传统多重性调整方法。
Stat Med. 2013 Dec 20;32(29):5172-218. doi: 10.1002/sim.5990. Epub 2013 Sep 30.
9
Advanced multiplicity adjustment methods in clinical trials.临床试验中的先进多重性调整方法。
Stat Med. 2014 Feb 20;33(4):693-713. doi: 10.1002/sim.5974. Epub 2013 Sep 16.
10
Design of oncology clinical trials: a review.肿瘤临床试验设计:综述。
Crit Rev Oncol Hematol. 2013 Oct;88(1):144-53. doi: 10.1016/j.critrevonc.2013.03.007. Epub 2013 Apr 25.